Comparative Pharmacology
Head-to-head clinical analysis: OVCON 50 versus ZOVIA 1 35E 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OVCON 50 versus ZOVIA 1 35E 28.
OVCON-50 vs ZOVIA 1/35E-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive; suppresses gonadotropin release, inhibiting ovulation, and alters cervical mucus and endometrial lining.
ZOVIA 1/35E-28 is a combined oral contraceptive (COC) containing ethinyl estradiol and norethindrone. It inhibits ovulation via suppression of gonadotropins (FSH and LH), increases cervical mucus viscosity, and alters endometrial receptivity.
One tablet (norethindrone 1 mg and ethinyl estradiol 50 mcg) orally once daily for 21 days followed by 7 days of placebo or no tablets.
One tablet orally once daily at the same time each day for 21 days, followed by 7 days of placebo (inactive tablets), then repeat.
None Documented
None Documented
Norethindrone: 5-14 hours (terminal); ethinyl estradiol: 7-20 hours. Clinical context: Steady-state reached within 5-7 days; half-life allows once-daily dosing with stable contraceptive efficacy.
Ethinyl estradiol: ~17 hours (range 13-27 hours); Norethindrone: ~8 hours (range 5-14 hours). Clinical context: Steady state achieved in ~5-7 days; contraceptive effect requires consistent dosing.
Renal: 40-60% (metabolites, primarily glucuronide conjugates; <1% unchanged). Fecal: 30-50% (via biliary elimination).
Renal: ~40% as metabolites; biliary/fecal: ~40% as metabolites; unchanged drug minimal (<1%).
Category C
Category C
Oral Contraceptive
Oral Contraceptive